Value proposition

We enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.


Nexstim is a Finnish, globally operating medical technology company.

Founded in 2000 in Helsinki, Finland, Nexstim is committed to improving the quality of life of patients with significant unmet clinical needs. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

SmartFocus® technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.

In addition, Nexstim is commercializing its SmartFocus® based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.

Nexstim shares are listed on Nasdaq First North Growth Market Finland.

TMS, nTMS, Brain Mapping, and Transcranial Magnetic Stimulation